Stockholm, 23 February 2021: Today, Lipidor AB publishes its year-end report for the period 1 January – 31 December 2020. The report is available on the company's website lipidor.se (https://lipidor.se/lipidor-ab-bokslutskommunik-2020/) and in the attached pdf. Summary of quarterly report – Q4 2020 A quarter of high activity and more important milestones including: redemption of warrants amounting […]
STOCKHOLM, Sweden, 18 January 2021 – Lipidor AB (Nasdaq First North:LIPI) today announced that the Company has signed an exclusive licensing agreement with Cannassure Therapeutics Ltd. (TASE:CSURE), an Israeli company specializing in the development and manufacture of innovative medicinal cannabis products. Under the agreement, Cannassure has the exclusive right to use Lipidor's proprietary drug delivery […]
STOCKHOLM, Sweden, 16 December 2020 – Lipidor AB (Nasdaq First North:LIPI) announced today that the Company has signed a new cooperation agreement with Aurena Laboratories AB. Over a five-year period, Lipidor will invest up to SEK 15 million in the new collaboration. Under the agreement, Aurena Laboratories will establish a production unit to meet the […]
Stockholm, 27 November 2020 – Lipidor’s Annual General Meeting on 11[th] June 2020, adopted an instruction regarding the appointment of the Nomination Committee. Pursuant to this instruction the Nomination Committee should comprise of four members. The three principal shareholders who are registered by Euroclear Sweden AB on the last day of September prior to the […]
STOCKHOLM, 19 August 2020: Today, Lipidor AB publishes its interim report for the period July – September 2020. The quarterly report is available on the company's website lipidor.se (https://lipidor.se/investors/financial-reports/interim-reports/) and in the attached pdf. Summary of the interim report – third quarter 2020 A quarter of high activity and many important milestones, including: a directed share […]
Stockholm, 1 October 2020: Lipidor AB (Nasdaq First North: LIPI) today announces that the company is strengthening its management team through the recruitment of Anders Hagman as Chief Development Officer. Hagman will assume the role as of 1 October 2020. Lipidor's growth journey continues, and the completion of the management team is a key step […]
Stockholm, 30 September 2020 – Lipidor AB (Nasdaq First North:LIPI) today announces a positive outcome of the feasibility study into the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. The study was conducted in collaboration with Cannassure Therapeutics Ltd. (TASE:CSURE), an Israeli company specializing in the development and […]
In the last press release, Lipidor published that the information and interim report was such that Lipidor is required to publish under the EU Market Abuse Regulation. This was incorrect as the interim report for H1 2020 contains no insider information. This has been corrected in this press release. Today, Lipidor AB publishes its interim […]
Today, Lipidor AB publishes its interim report for the period January – June 2020. The quarterly report is available on the company's website lipidor.se (https://lipidor.se/investors/financial-reports/interim-reports/) and in the attached pdf. Summary of the interim report – second quarter 2020 Lipidor has continuous positive ongoing out-licensing discussions with potential licensees. Preperations for initiation of the phase lll-study […]
Today, 11 August 2020, Lipidor AB (publ) (the “Company” or “Lipidor”) held an extraordinary general meeting (“EGM”) in Solna, Sweden. The EGM resolved upon, inter alia, the following resolutions. Resolution on approval of the Company’s subsidiary Emollivet AB’s (the “Subsidiary” or “Emollivet”) resolution on a new issue of shares The EGM resolved unanimously to approve […]